Jonah Feldman

Articles

ARV-766 Demonstrates Clinical Activity in AR LBD–Mutated Metastatic CRPC

June 10th 2024

The investigational PROTAC AR degrader ARV-766 showed promising clinical activity and tolerability in patients with metastatic castration-resistant prostate cancer.

Study Evaluates Synergistic Potential of Nab-Sirolimus Plus Letrozole in Advanced/Recurrent Endometrial Cancer

March 17th 2024

The activity of nab-sirolimus plus letrozole is under study in patients with advanced or recurrent endometrioid endometrial cancer.

Later-Line Ruxolitinib Use Produces Ongoing Benefit in Real-World Patients With cGVHD

February 25th 2024

Real-world ruxolitinib use in chronic GVHD was primarily in the second- or third-line, lasted for a median of 8 months, and involved dose adjustments.

Immune Engager Therapies Demonstrate Promise Following Relapse on Ide-Cel in Multiple Myeloma

February 23rd 2024

Treatment with immune engager therapies following relapse on ide-cel resulted in better median PFS vs other therapies for patients with multiple myeloma.

Post-Hoc Analysis of ARASENS Reinforces Use of Darolutamide/ADT/Docetaxel Combo as SOC in mHSPC

January 25th 2024

A post-hoc analysis of censored patients with mHSPC showed benefit with darolutamide, ADT, and docetaxel, supporting primary data from the ARASENS trial.

Obe-Cel Elicits High Remission Rates in R/R B-ALL Irrespective of Leukemic Burden

December 10th 2023

Obecabtagene autoleucel elicited durable responses in patients with relapsed or refractory B-cell acute lymphoblastic leukemia independent of leukemic burden at lymphodepletion, although better outcomes were observed in those with lower burden.

Lenvatinib/Pembrolizumab/Chemo Is Safe With Early Efficacy Signals in mESCC

October 23rd 2023

The combination of lenvatinib, pembrolizumab, and chemotherapy had a manageable safety profile and elicited preliminary antitumor activity in patients with metastatic esophageal squamous cell carcinoma.

Durcabtagene Autoleucel Demonstrates Rapid Proliferation and Persistence in Relapsed/Refractory Myeloma

September 28th 2023

Use of the novel T-charge rapid manufacturing platform for the production of durcabtagene autoleucel CAR T cells within 2 days was successful in producing rapid and robust in vivo expansion, as well as long-term T-cell persistence in patients with relapsed/refractory multiple myeloma, according to a correlative analysis of data from an ongoing phase 1 trial presented at the 2023 IMS Annual Meeting.

Iflinatamab Deruxtecan Elicits Clinical Activity in SCLC

September 10th 2023

Treatment with the antibody-drug conjugate ifinatamab deruxtecan in heavily pretreated patients with small cell lung cancer led to promising efficacy and a manageable safety profile.

Fianlimab/Cemiplimab Demonstrates Early Clinical Activity and Safety in Advanced Melanoma

June 6th 2023

The LAG-3 inhibitor fianlimab plus cemiplimab produced high and consistent tumor responses and a comparable toxicity profile to that of anti–PD-L1 monotherapies in patients with advanced melanoma who were PD-L1 inhibitor–naïve in the advanced setting, according to data from a phase 1 study.

BRCA Mutations Associated with Worse Survival in HRR-deficient mCRPC

June 4th 2023

Patients with homologous recombination repair–deficient mutations and metastatic castration-resistant prostate cancer who also harbored BRCA mutations experienced poorer survival outcomes vs patients without BRCA mutations and those with non-BRCA HRR mutations, according to an analysis from the CAPTURE trial.

Eftilagimod Alpha/Pembrolizumab Generates Antitumor Activity in PD-1–Resistant NSCLC

April 3rd 2023

Treatment with eftilagimod alpha plus pembrolizumab resulted in tumor shrinkage and a tolerable safety profile in patients with anti–PD-1/PD-L1–resistant non–small cell lung cancer.

Ruxolitinib Displays Variable Pharmacokinetics in Patients with GVHD 2 Years of Age and Under

February 17th 2023

A study did not find a correlation between the pharmacokinetics and pharmacodynamics of ruxolitinib for the treatment of patients 2 years of age and younger with graft-vs-host disease.

MRD Detection Provides Prognostic Value in Patients With ALL Undergoing HCT

February 16th 2023

The presence of minimal residual disease led to a higher likelihood of relapse in patients with acute lymphoblastic leukemia who underwent hematopoietic cell transplant compared with those who had undetectable MRD pre and post transplant.

Tislelizumab Provides QOL Benefit Over Sorafenib in Unresectable HCC

January 21st 2023

Tislelizumab monotherapy resulted in favorable health-related quality of life outcomes compared with sorafenib as frontline treatment for patients with unresectable hepatocellular carcinoma.

Palbociclib Plus Fulvestrant Fails to Improve PFS in ER+/HER2- Breast Cancer After Progression on a CDK4/6 inhibitor

December 8th 2022

Palbociclib plus fulvestrant did not elicit a progression-free survival benefit vs fulvestrant alone in patients with estrogen receptor–positive/HER2-negative breast cancer who had progressed on prior treatment with a CDK4/6 inhibitor and aromatase inhibitor.

Trastuzumab Deruxtecan at Reduced Dose Maintains Efficacy in HER2-Mutated NSCLC

September 12th 2022

The clinical benefit and tolerable safety profile of trastuzumab deruxtecan was maintained at 5.4 kg/mg vs 6.4 kg/mg in patients with HER2-mutated non–small cell lung cancer, confirming the benefit-risk ratio of the FDA-approved dose.

Isatuximab Plus Carfilzomib/Dexamethasone Maintains Survival Benefit in Relapsed Multiple Myeloma

August 26th 2022

The combination of Isatuximab plus carfilzomib and dexamethasone continued to demonstrate a progression-free survival benefit vs carfilzomib and dexamethasone alone in relapsed multiple myeloma.

Isatuximab-Based Regimens Demonstrate Favorable Safety in Relapsed/Refractory Multiple Myeloma

August 26th 2022

Isatuximab-containing regimens displayed favorable toxicity in patients with relapsed/refractory multiple myeloma in a real-world study.

Larotrectinib Demonstrates Favorable Long-Term Responses in NTRK Fusion–Positive Lung Cancer

August 6th 2022

Larotrectinib continued to elicit durable responses and a low toxicity profile in patients with NTRK fusion–positive lung cancer, according to long-term follow-up data from the phase 2 NAVIGATE trial and phase 1 LOXO-TRK-14001 trial.